These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25739728)

  • 1. Advancements in the delivery of epigenetic drugs.
    Cramer SA; Adjei IM; Labhasetwar V
    Expert Opin Drug Deliv; 2015; 12(9):1501-12. PubMed ID: 25739728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy.
    Chen F; Shi Y; Zhang J; Liu Q
    Curr Drug Targets; 2020; 21(11):1084-1098. PubMed ID: 32410563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer.
    Ghosh A; Himaja A; Biswas S; Kulkarni O; Ghosh B
    Mol Pharm; 2023 Dec; 20(12):5981-6009. PubMed ID: 37899551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenomics in stress tolerance of plants under the climate change.
    Kumar M; Rani K
    Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of epidrugs.
    el Bahhaj F; Dekker FJ; Martinet N; Bertrand P
    Drug Discov Today; 2014 Sep; 19(9):1337-52. PubMed ID: 24680930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology.
    Csoka AB; Szyf M
    Med Hypotheses; 2009 Nov; 73(5):770-80. PubMed ID: 19501473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Neuropharmacology: Drugs Affecting the Epigenome in the Brain.
    Toth M
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():181-201. PubMed ID: 32997604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoepigenetics: an element of personalized therapy?
    Majchrzak-Celińska A; Baer-Dubowska W
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):387-398. PubMed ID: 27860490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis of Targeted Imaging and Therapy in Cancer Explorations with the Epigenetic Drugs.
    Pandit P; Brahmkhatri V
    Subcell Biochem; 2022; 100():503-521. PubMed ID: 36301504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical methods to promote drug delivery on mucosal tissues of the oral cavity.
    Giannola LI; Sutera FM; De Caro V
    Expert Opin Drug Deliv; 2013 Oct; 10(10):1449-62. PubMed ID: 23802558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders.
    Mittal R; Patel AP; Jhaveri VM; Kay SS; Debs LH; Parrish JM; Pan DR; Nguyen D; Mittal J; Jayant RD
    Expert Opin Drug Deliv; 2018 Mar; 15(3):301-318. PubMed ID: 29272976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating epigenetic modifications for cancer therapy (Review).
    Castro-Muñoz LJ; Ulloa EV; Sahlgren C; Lizano M; De La Cruz-Hernández E; Contreras-Paredes A
    Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36799181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs.
    Baer-Dubowska W; Majchrzak-Celińska A; Cichocki M
    Pharmacol Rep; 2011; 63(2):293-304. PubMed ID: 21602587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery.
    Berman M; Mattheolabakis G; Suresh M; Amiji M
    Expert Opin Drug Deliv; 2016 Jul; 13(7):987-98. PubMed ID: 27097309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.
    Cooper DL; Conder CM; Harirforoosh S
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1661-80. PubMed ID: 25054316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics primer: why the clinician should care about epigenetics.
    Duarte JD
    Pharmacotherapy; 2013 Dec; 33(12):1362-8. PubMed ID: 23864439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic prospects for epigenetic modulation.
    Heightman TD
    Expert Opin Ther Targets; 2011 Jun; 15(6):729-40. PubMed ID: 21366500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs).
    Kankala RK; Xu PY; Chen BQ; Wang SB; Chen AZ
    Adv Drug Deliv Rev; 2021 Sep; 176():113846. PubMed ID: 34197896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.
    Bouyahya A; Mechchate H; Oumeslakht L; Zeouk I; Aboulaghras S; Balahbib A; Zengin G; Kamal MA; Gallo M; Montesano D; El Omari N
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.